2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchMeSH KeywordsFlow CytometryHumansLymphoma, T-CellLymphoma, T-Cell, PeripheralPrognosisRetrospective StudiesConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphomaT-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 285-308. PMID: 35276674, DOI: 10.6004/jnccn.2022.0015.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAnaplastic large cell lymphomaLarge cell lymphomaAnaplastic lymphoma kinaseCell lymphomaLymphoma kinaseTreatment of PTCLNCCN Clinical Practice GuidelinesAngioimmunoblastic T-cell lymphomaClinical practice guidelinesNon-Hodgkin lymphomaMature T cellsNCCN guidelinesLymphoproliferative disordersCommon subtypePractice guidelinesT cellsLymphomaHeterogeneous groupGuidelinesSubtypesDiagnosisOncologySafety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
2020
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinib
2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2015
Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma
Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-1015.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllograftsAutograftsBiopsy, NeedleFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHematopoietic Stem Cell TransplantationHumansImmunohistochemistryLymphoma, T-CellLymphoma, T-Cell, CutaneousMaleMiddle AgedPanniculitisPositron-Emission TomographyRetrospective StudiesRisk AssessmentSampling StudiesSkin NeoplasmsTreatment OutcomeConceptsHematopoietic stem cell transplantationT-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaAllogeneic hematopoietic stem cell transplantationPanniculitis-like T-cell lymphomaCutaneous T-cell lymphomaStem cell transplantationPCGD-TCLCell transplantationPrimary cutaneous γδ T-cell lymphomaCutaneous γδ T-cell lymphomaAutologous hematopoietic stem cell transplantationOutcome of HSCTAdvanced-stage mycosis fungoidesΓδ T-cell lymphomaPanniculitic T-cell lymphomaAggressive T-cell lymphomaMatched-related donorsMatched-unrelated donorsT-cell infiltratesPromising treatment modalityAggressive therapyMost patientsMycosis fungoidesInferior outcomes
2012
Pralatrexate: treatment of T-cell non-Hodgkins lymphoma
Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkins lymphoma. Future Oncology 2012, 9: 21-29. PMID: 23252560, DOI: 10.2217/fon.12.168.Peer-Reviewed Original ResearchConceptsRefractory peripheral T-cell lymphomaPeripheral T-cell lymphomaT-cell non-Hodgkin lymphomaVitamin B12 supplementationOverall response rateNon-Hodgkin lymphomaT-cell lymphomaPROPEL trialCommon toxicitiesB12 supplementationPatient populationClinical studiesResponse ratePralatrexateUS FDALymphomaMetabolic inhibitorsTreatmentToxicityNauseaThrombocytopeniaDoseTrialsSupplementationWeeks
2011
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma
Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opinion On Drug Metabolism & Toxicology 2011, 7: 1141-1152. PMID: 21726160, DOI: 10.1517/17425255.2011.595404.Peer-Reviewed Original ResearchMeSH KeywordsAminopterinAntineoplastic AgentsClinical Trials as TopicDrug Evaluation, PreclinicalFolic Acid AntagonistsHumansLymphoma, T-CellConceptsPeripheral T-cell lymphomaT-cell lymphomaRefractory peripheral T-cell lymphomaPhase I/II trialEarly phase I/II trialsCutaneous T-cell lymphomaAggressive T-cell lymphomaT-cell lymphoma subtypesFrequent adverse eventsStem cell transplantationT-cell neoplasmsII trialAdverse eventsMost patientsHodgkin's diseasePreclinical findingsClinical efficacyLymphoma trialsPoor outcomeConventional therapyHodgkin's lymphomaReversible thrombocytopeniaHematologic malignanciesClinical trialsClinical studiesMolecular Predictors of Response in Aggressive T-cell Lymphomas
Foss FM. Molecular Predictors of Response in Aggressive T-cell Lymphomas. The Cancer Journal 2011, 17: 142-148. PMID: 21427558, DOI: 10.1097/ppo.0b013e31821828b7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorGene Expression ProfilingHumansLymphoma, T-CellMolecular Targeted TherapyNeoplasm StagingPrognosisConceptsAggressive T-cell lymphomaT-cell lymphomaNatural killer cellsNon-Hodgkin lymphomaWorld Health OrganizationKiller cellsInferior outcomesPrognostic characterizationMore accurate diagnosisTreatment strategiesMolecular predictorsTherapeutic strategiesAccurate diagnosisDistinct entityLymphomaGene expression profilingHealth OrganizationHeterogeneous groupRecent dataMolecular featuresDevelopment of novelExpression profilingMolecular analysisRegimensMalignancy
2010
Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaPTCL subtypesTherapeutic regimensDisease state awarenessAggressive disease courseT-cell markersB-cell lymphomaMost patientsRefractory diseaseDisease courseIndolent courseAggressive diseaseLymphoproliferative disordersPoor prognosisTherapeutic overviewEffective treatmentProper diagnosisLymphomaRegimensSubtypesHeterogeneous groupPatientsPrognosisDisease
2009
Advances in the treatment of T-cell lymphomas.
Foss F. Advances in the treatment of T-cell lymphomas. Clinical Advances In Hematology And Oncology 2009, 7: 1-14; quiz 15-6. PMID: 20068547.Peer-Reviewed Original Research
2005
Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma
Huang Z, Higgins B, Foss F. Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2005, 6: 43-45. PMID: 15989706, DOI: 10.3816/clm.2005.n.026.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsGalliumHumansLymphoma, T-CellMiddle AgedTomography, X-Ray ComputedTreatment Outcome